NHP Systemic Lupus Erythematosus (SLE) Model

SLE is a complex autoimmune disease characterized by autoantibody production, immune complex deposition, and multi‑organ damage (skin, joints, kidneys). HKeyBio offers a well‑characterized TLR‑7 agonist induced NHP SLE model that recapitulates key human features: elevated anti‑dsDNA, IFN‑α signature, and kidney pathology. This model provides a robust platform for efficacy testing of novel immunomodulators and supports IND‑enabling studies with comprehensive data packages.

Quantity:
Availability:





Inquire Add to Basket

Product Description

Key Features & Benefits

Clinically relevant Mimics human SLE pathogenesis: autoantibodies, interferon signature, glomerulonephritis.

TLR-7 agonist induction Reliable, reproducible model with well-defined kinetics (anti-dsDNA, IFN-α).

Multi-endpoint analysis Includes anti-dsDNA, IFN-α, complement, kidney histology, and transcriptomics.

IND-ready data packages Studies can be conducted in accordance with GLP principles.

Customizable protocols Dose optimization, combination therapy, and biomarker exploration available.

Technical Data & Validation

Representative data from our NHP SLE model：

TLR-7 Agonist Induced NHP SLE Model

Applications

• Efficacy testing of immunomodulatory drugs (biologics, small molecules, nucleic acid therapeutics)

• Target validation for SLE and lupus nephritis

• Biomarker discovery and validation (anti-dsDNA, IFN signature, complement factors)

• IND-enabling toxicology and safety pharmacology studies

• Mechanism of action (MOA) investigations

Model Specifications

Parameter	Specification
Species	Cynomolgus macaque (Macaca fascicularis)
Induction method	TLR-7 agonist (imiquimod) topical + repeated dosing
Study duration	4–12 weeks (depending on endpoints)
Key endpoints	Anti-dsDNA, ANA, IFN-α, complement C3/C4, kidney histology (H&E, IF), RNA-seq
Data package	Raw data, analysis reports, IHC slides, bioinformatics (optional)

❓ Frequently Asked Questions

Q1: What SLE preclinical models do you provide?

A1: We offer a full portfolio of SLE models, including MRL/lpr spontaneous model, Pristane, TLR-7 agonist, ALD-DNA and apoptotic cell induced models using C57BL/6 and BALB/c mice.

Q2: What are the modeling mechanisms?

A2: Spontaneous MRL/lpr mice develop autoimmune disorders naturally. Chemical or agent induction triggers abnormal immune activation, autoantibody production and immune complex deposition, fully recapitulating the pathogenesis of human SLE.

Q3: What evaluation indicators are adopted?

A3: We monitor body weight, organ indexes and lymphadenopathy. We detect anti-dsDNA antibodies and proteinuria, analyze immune cell subsets, and perform HE staining for kidney and heart pathological assessment.

Q4: What are the experimental cycles?

A4: Cycles vary by model: ALD-DNA induced model lasts 12 weeks, Pristane model runs 26 weeks, TLR-7 agonist model takes 12 weeks, and the MRL/lpr spontaneous model is observed from Week 10 to Week 22.

Q5: What are the advantages and applications?

A5: These models feature stable autoimmune symptoms and high similarity to human SLE. They are ideal for efficacy screening, mechanism research and preclinical evaluation of targeted drugs for systemic lupus erythematosus.